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Abstract
Background: Multiple studies have shown that brain gene expression is disturbed in subjects
suffering from schizophrenia. However, disentangling disease effects from alterations caused by
medication is a challenging task. The main goal of this study is to find transcriptional alterations in
schizophrenia that are independent of neuroleptic treatment.
Methods: We compared the transcriptional profiles in brain autopsy samples from 55 control
individuals with that from 55 schizophrenic subjects, subdivided according to the type of
antipsychotic medication received.
Results: Using global and high-resolution mRNA quantification techniques, we show that genes
involved in immune response (GO:0006955) are up regulated in all groups of patients, including
those not treated at the time of death. In particular, IFITM2, IFITM3, SERPINA3, and GBP1 showed
increased mRNA levels in schizophrenia (p-values from qPCR ≤ 0.01). These four genes were co-
expressed in both schizophrenic subjects and controls. In-vitro experiments suggest that these
genes are expressed in both oligodendrocyte and endothelial cells, where transcription is inducible
by the inflammatory cytokines TNF-α, IFN-α and IFN-γ.
Conclusion:  Although the modified genes are not classical indicators of chronic or acute
inflammation, our results indicate alterations of inflammation-related pathways in schizophrenia. In
addition, the observation in oligodendrocyte cells suggests that alterations in inflammatory-related
genes may have consequences for myelination. Our findings encourage future research to explore
whether anti-inflammatory agents can be used in combination with traditional antipsychotics for a
more efficient treatment of schizophrenia.
Background
Genome-wide expression analysis can be used to identify
associations between gene products and disease inde-
pendently of a-priori hypothesis. This approach has been
used several times to study schizophrenia post-mortem
brain tissues as reviewed previously [1,2]. Even though
these studies included a very limited number of brain
samples, multiple replications support a decreased expres-
sion of oligodendrocyte and myelin-related genes in
schizophrenia [3-7]. However, transcriptional distur-
bances in patients are by nature subject to the confound-
ing effect of the medication used to treat the disease, and
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this issue has received little attention, partly due to sample
size limitations for studies based on human autopsy brain
samples.
We have previously used a hypothesis driven approach to
examine the expression levels of the RNA binding protein
QKI and six oligodendrocyte related (OR) genes in post-
mortem frontal cortex samples [8,9]. Our results indicated
that QKI regulates the mRNA levels of myelin and oli-
godendrocyte genes in the human brain, and that changes
in the balance between QKI splice variants may be linked
to altered myelination in schizophrenia. We also showed,
using a large collection of brain autopsies from 55
patients and 55 controls, that the modification in OR gene
expression varied with the type of medication received [8].
These results demonstrated the importance of incorporat-
ing medication as a factor in the analysis of transcriptional
changes in schizophrenia.
In this study, we have widened our scope and use a data
driven approach to identify additional transcriptional
changes that are independent of the medication received
by the patients. There was only one gene ontology (GO)
category that was over-represented among genes with
modified expression in schizophrenic subjects that was
independent of medication, and four of the genes in this
group are induced by inflammatory cytokines. Our results
may provide initial molecular markers to support the per-
haps controversial theory that postulates that inflamma-
tion or inflammation-related processes may be key
features behind schizophrenia [10-14]. To evaluate
whether the observed transcriptional disturbance may
have consequences for the micro-vascular system and
myelin production in the brains of patients, we also stud-
ied the mRNA levels in-vitro in both endothelial and oli-




Autopsies from 110 individuals were obtained from three
brain banks and each collection contained an equal
number of tissue samples from individuals diagnosed
with schizophrenia and individuals without psychiatric
diagnosis that were used as controls. The same sample set
was previously used for the analysis of myelination-
related genes [8,15]. The Stanley Foundation Brain Con-
sortium (Bethesda, USA) contributed with brain autopsies
from 30 individuals, 48 samples were provided by Maud-
sley Brain Bank (Institute of Psychiatry, Dept. of Neuropa-
thology, London, UK) and 32 came from Harvard Brain
Tissue Resource Centre (Massachusetts General Hospital,
Massachusetts, USA). The diagnostic criterion used by the
Stanley foundation was DSM-IV, whereas the Maudsley
brain bank used ICD-10 and the Harvard Resource Centre
used the Feighner criteria. Forty-six samples were from
females and 64 were from males. In total 110 tissue sam-
ples from frontal cortex, Brodmann area 8 and 9 (from
Harvard and Stanley brain banks) and the left side of the
superior frontal gyrus (from Maudsley brain bank), were
included in the study. The mean time post mortem was
34.3 hours for controls (standard deviation 22.6) and
34.6 hours for schizophrenic subjects (standard deviation
20.5), where as the average age of controls and affected
subjects were 58.5 (18.0) and 54.7 (17.3), respectively.
Fifty-five tissue samples came from controls (CTRL) and
55 from patients. Seven of the schizophrenic (SCH) indi-
viduals were treated with atypical neuroleptics (ATYP),
nineteen were treated with typical neuroleptics (TYP) and
eleven schizophrenic individuals were not treated with
neuroleptics prior to death (NTD). For the remaining
eighteen schizophrenic individuals no information
regarding medication was available (UNKNW). The typi-
cal neuroleptics group included patients treated with
chlorpromazine, promazine, haloperidol, thioridazine,
stelazine, trifluroperazine, thiothixene and sulpiride. The
atypical neuroleptics group included patients treated with
clozapine and risperidone. Each autopsy sample consisted
of 300 mg to 500 mg of prefrontal cortex tissue with sim-
ilar amounts of grey and white matter in each sample.
Moreover, duplicate autopsies were collected from each
individual to control for differences in the proportion of
white matter in each sample.
Demographic information about each individual has
been loaded to the miame express database (ArrayExpress
accession number E-MEXP-857) and a detailed descrip-
tion of each subject can also be found in Supplementary
Table 1. Ethical approval for the use of these samples was
received according to Swedish regulations (Ups dnr
99277).
Microarray hybridization
To identify genes that differed in mRNA expression levels
between all schizophrenic patients and controls or
between a patient subgroup and controls we carried out
several different microarray experiments. Messenger RNA
from all individuals was combined into five sample pools,
with each individual in a pool contributing with an equal
amount of mRNA. The mRNA samples were pooled as fol-
lows: patients treated with typical neuroleptics (TYP, n =
19), patients treated with atypical neuroleptics (ATYP, n =
7), patients that did not receive any neuroleptics at the
time of death (NTD, n = 11), all control individuals
(CTRL, n = 55), and all schizophrenic patients (n = 55).
One hundred ng from each of the four schizophrenic
mRNA pool was hybridized together with 100 ng mRNA
from the control pool on slides printed with 29 750
human cDNA clones [16]. Detailed information on the
array designs is available on ArrayExpress (accessionBMC Psychiatry 2007, 7:46 http://www.biomedcentral.com/1471-244X/7/46
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number A-MEXP-114). Each hybridization was repeated
four times, with the dye assignment reversed in the two of
the hybridizations (dye swap pairs), resulting in a total of
16 microarrays.
The MICROMAX TSA™ Labeling and Detection kit (NEN®
Life Science Products, Inc.) was used to label the sample
pools with Cyanine-3 (Cy-3) and Cyanine-5 (Cy-5)
respectively. The TSA™ procedure was performed accord-
ing to manufacturer's protocols.
Microarray analysis
The microarrays were scanned at 10 µm resolution using
a GenePix 4100A scanner (Axon Instruments, Inc.). Spots
on the resulting images were quantified with the software
package GenePix Pro 5.0 (Axon Instruments, Inc.). The
mean intensity of the two samples (Cy5-labelled sample =
R, the Cy3-labelled sampled = G) were used to calculate
the log-transformed ratio between the two samples for
each spot: M = log2 (R/G). Microarray data was submitted
to ArrayExpress.
Prior to the analysis of the microarray data, we used a
robust scatter plot smoother (Proc Loess, SAS v8.2) to per-
form a sub-array intensity-dependent normalization of M,
with the smoothing parameter set to 40%. All spots with
a mean spot intensity below the local median background
were excluded from the analysis. To identify genes that
were differentially expressed in at least one patient sub-
group, we analyzed the signals from the clones on all 16
arrays with a regression model (Proc GLM, SAS v8.2). In
the model the normalized log-transformed ratio y of array
j was modelled as a function of schizophrenic subgroup:
where β0 referrers to the intercept, xi refers to the four
design variables NTD, TYP, ATYP and UNKWN, and βi to
the corresponding regression coefficient estimating the
mRNA difference between subgroup i and the control. The
arrays containing samples from all the schizophrenic
patients was represented by the sum of all four design var-
iables, each multiplied by the fraction of individual con-
tributing to the specific subgroups. To identify common
mRNA responses in all the three subgroups with known
medication status, we also tested whether the mean of the
three estimated responses (βi) differed from zero (n = 3).
We penalized all F-ratio by adding a constant (a0) to the
denominator and choose a0 to be the 90th percentile of the
mean square errors of all analyzed clones. We considered
penalized F-ratios above 7 to be indicative of a differential
expression for a schizophrenic subgroup, and a penalized
F-ratio above 2.2 to indicate a common response in the
three subgroups as determined by a 10,000 permutations.
The cut-offs values corresponded to four expected false
positives for each clone list.
Overrepresentation of a biological function within a list of
selected genes was assessed with GOstat [17,18]. That is,
to assess statistically overrepresentation we compared the
observed frequencies of genes within Gene Ontology
(GO) classes for a list of selected clones with the frequen-
cies of all genes represented by all analyzed clones, using
the FDR option to correcting for multiple testing. We only
considered the biological function hierarchy, and used a
minimal GO path length of five.
Real-time RT PCR
All samples, without pooling, were analysed by real-time
RT PCR. Tissue sample preparation, total RNA prepara-
tion, poly-A RNA purification as well as the reverse tran-
scription reactions were performed as previously
described [19]. Briefly, total RNA was prepared using Tri-
zol reagent (Life Technologies, Sweden), mRNA was
extracted using the PolyATtract mRNA isolation system
(Promega SDS, Sweden) and reverse transcription
employed Superscript II (Life Technologies, Sweden). The
110 individuals, covering 55 patients and 55 controls,
were distributed in duplicates on three plates according to
a balanced incomplete block design, with respect to diag-
nosis, sex and brain bank. Real-time RT-PCR was per-
formed with an ABI PRISM 7000 Sequence Detection
System (Applied Biosystems, Foster City, USA) as follows:
2 minutes at 50°C and 10 minutes at 95°C followed by
40 cycles of 15 seconds at 95°C and 1 minutes at 60°C.
Each reaction was carried out in a total volume of 25 µl,
consisting of 9.8 µl TaqMan universal PCR master mix,
0.125 µM probe (Applied Biosystems, Foster City, USA),
0.25 µM of each primer (Thermo Electron Cooperation,
Germany) and ~ 10–100 ng of cDNA.
The primer/probe-set for the reference genes (ACTB and
GAPD) as well as for the IFITM2, IFITM3 and MAG were
uniquely designed using Primer Express (Applied Biosys-
tems, Foster City, USA). Primers for TF, SCD, SERPINA3,
GBP1 and HLA-A were ordered as "Assay on Demand"
(Applied Biosystems, Foster City, USA). The expression
data was collected with the ABI PRISM 7000 SDS software
(Applied Biosystems, Foster City, USA).
qPCR analysis
To test if the expression of the target genes were disturbed
in patients suffering from schizophrenia and/or affected
by patient sub-group with respect to neuroleptic treat-
ment, we analyzed the mRNA levels with an ANCOVA
model (Proc GLM, SAS 8.2) as we previously described
[8]. The model included the main factors disease (SCH/
CTRL), and disease subgroup (ATYP, TYP, NTD) nested
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medication status were included in the comparisons of all
patients versus controls, but they were excluded in the test
of patient subgroups. In addition, we included the cate-
gorical factors brain bank, gender, and replicate PCR-
plate, and the covariates, age, post-mortem time and ref-
erence gene expression (the geometric mean of ACTB and
GAPD) to account for the effects of these variables on
mRNA levels of the target genes. We used logarithmic
transformed expression data and averaged the mRNA lev-
els obtained from the duplicate samples from each indi-
vidual prior to the statistical analysis.
The co-expression patterns of genes that were differen-
tially expressed in schizophrenic subjects and/or varied
between schizophrenic subgroups (IFITM2, IFITM3,
SERPINA3, GBP1, SCD, MAG and TF) were explored for
schizophrenic subjects and controls respectively. Target
gene expression was normalized, prior to the analysis, by
fitting the linear model described above to the observed
data (Proc GLM, SAS 8.2). The difference between the
observed and the fitted values (i.e. the residuals) were
considered the normalized expression level, and all pair-
wise Pearson correlation coefficients were calculated.
Cell cultures and interferon treatment
Human telomerase-immortalized dermal microvascular
endothelial cells (TIME) [20], were cultured in EBM MV2
growth medium (Promocell). The human oligodendro-
cyte-derived cell line (HOG)[21] was kept in Dulbecco's
modified Eagle's medium (DMEM) with low glucose and
GlutaMAX (Invitrogen), supplemented with 5% fetal
bovine serum and 1% penicillin/streptavidin. TIME and
HOG cells were treated for 3, 8, 24 or 48 hours with either
10 ng/ml IFN-γ (Peprotech), 10 ng/ml IFN-α (Peprotech)
or 1 ng/ml TNF-α (R&D), and thereafter harvested for fur-
ther analysis. All cell culture experiments were performed
as independent triplicates. To test if the expression levels
of inflammatory genes were induced by cytokines in
human cell lines, we analyzed the mRNA levels of target
genes in each experiment with an ANCOVA model (Proc
GLM, SAS 8.2). The model included the main factors,
treatment (Cytokine addition vs CTRL), and time (3, 8,
24, 48 h) nested within treatment. In addition, we
included reference gene expression (ACTB) to account for
the systematic variation that was due to sample mRNA
concentration. Expression levels of target and reference
genes were log-transformed prior to the statistical analy-
sis.
Results
Analysis of expression differences that are independent of 
medication received
We first identified genes with a high probability of being
differentially expressed independently of neuroleptic
medication. Twenty-three clones showed large and con-
sistent mRNA differences across all three subgroups, as
indicated by the penalized F-ratio (Table 1). This number
of clones is approximately six times higher than the
expected number of four false positives (as determined by
10 000 permutations). When these 23 genes were classi-
fied with respect to their biological function, genes
involved in immune response (GO:0006955) corre-
sponded to approximately 25% of the GO-annotated
genes. This represents a strong overrepresentation, since
the frequency of immune response genes was only 2.6%
of all analyzed and annotated clones on the array (p-value
< 0.01). The five genes involved in immune response,
alpha-1-antichymotrypsin (SERPINA3), interferon-
induced transmembrane 2 and 3 (IFITM2 and IFITM3),
guanylate binding protein 1, interferon inducible (GBP1)
and major histocompatibility complex, class1, A (HLA-A),
were all up-regulated in schizophrenic patients (marked
with "*" in Table 1), indicating disturbances in inflamma-
tory-related responses.
Analysis of expression differences for each of the three 
patient subgroups separately
After the screening for genes that were differentially
expressed in schizophrenia independently of received
neuroleptic treatment, we identified clones that showed a
large average expression difference between schizophrenic
patients and controls, as compared to random technical
variation, for each of the three patient subgroups separately.
(The cut-off value for the ranking statistics was adjusted so
that four false positives were expected in each list due to
random technical variation). We note that this analysis
served a primarily exploratory purpose, as pooling does
not allow for estimation of population variance. Conse-
quently the results from any individual genes (Supple-
mentary tables 2–5) should be interpreted with extreme
caution, until mRNA levels have been quantified on an
individual level. Nevertheless, results based on multiple
genes are less likely to be affected by a few extreme values
and our results suggest that both the number and direc-
tion of differentially expressed genes may vary between
the three subgroups (Figure 1). In particular we note that
the group treated with atypical neuroleptics had approxi-
mately four times as many genes showing an average
expression deviations from the control group than other
schizophrenic subjects, and that the distribution of clones
showing increased or decreased mRNA levels strongly
depended on schizophrenic subgroups (p-value < 0.0001,
Fishers exact test). Although these preliminary findings
need to be confirmed on an individual level similar trends
have been reported from experiments with haloperidol
and risperidone on rats [22].
Real-time RT-PCR
Since the micro array screening for genes with common
response across all schizophrenic subgroups suggestedBMC Psychiatry 2007, 7:46 http://www.biomedcentral.com/1471-244X/7/46
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that genes involved in immune response (GO:0006955)
were of particular interest, we quantified mRNA levels of
five genes related to immune response (Table 1) in all
samples without pooling, using real-time reverse tran-
scription PCR (qPCR). These genes included SERPINA3,
IFITM2, IFITM3, HLA-A, and GBP1 (Table 2). We com-
pared the results from these genes with qPCR resuts
obtained for oligodendrocyte-related genes, including
transferrin (TF), Myelin associated glycoprotein (MAG)
and Stearoyl-CoA desaturase (SCD), as disturbed expres-
sion of oligodendrocyte releated genes have been repeat-
edly reported in schizophrenia, and as all three genes were
clearly down regulated on the arrays from subjects treated
with atypical neuroleptics (Supplementary table 5). Over-
all, there was a good correspondence between mRNA lev-
els estimated in the three patient subgroups by microarray
and qPCR analysis and the qPCR results confirmed the
microarray findings with the exception of HLA-A (r2 =
0.71, n = 21). That is, SERPINA3, IFITM2, IFITM3, and
GBP1 showed significantly higher qPCR mRNA levels in
schizophrenic subjects than in control individuals and
this response was shared by all three patient subgroups
(Table 2).
To rule out the possibility that increased mRNA levels of
immune response genes in schizophrenic subjects were
due to infectious disease at the time of death, we per-
formed two additional analyses. First, a senior physician
classified the death cause of all 110 subjects into two cat-
egories, "likely infectious" (bronchopneumonia, intra-
abdominal sepsis, multiple organ failure, peritonitis,
pneumonia, pulmonary tuberculosis) or "non-likely
infectious". The data was then re-analyzed, taking account
of the effect of infectious/non-infectious death cause as a
factor in the statistical analysis. In a second analysis we
excluded all subjects that died from a "likely infectious"
cause and we re-analysed the remaining patients and con-
trols. Both these analyses confirmed that mRNA levels of
SERPINA3, IFITM2, IFITM3 and GBP1 were increased in
schizophrenia and were not simply the consequence of an
infection immediately prior to death. P-values for the four
genes were 0.003, 0.004, 0.004, 0.023 for the analysis
Table 1: Clones with differential expression patterns across all patient subgroups
Fold Change









1592837 IFITM2* 2.7 1.5 2.1 11.3 0.024 11p15.5
809910 IFITM3* 4.3 1.6 1.8 10.1 0.032 11p15.5
450533 SERPINA3* 4.5 1.2 7.8 8.4 0.056 14q32.1
1455976 IFITM2* 2.3 1.4 2.3 7.0 0.061 11p15.5
166245 GRIN1 -1.6 -1.3 -1.4 4.7 0.004 9q34.3
362926 PRKACB 1.4 1.7 1.5 4.6 0.012 1p36.1
323371 APP -2.9 -1.8 -1.7 4.2 0.083 21q21.2
841008 GBP1* 2.0 1.7 -1.0 4.1 0.079 1p22.2
221828 KIF1A -1.3 -1.5 -1.5 4.0 0.005 2q37.3
853906 HLA-A* 1.1 1.5 1.6 3.8 0.045 6p21.3
363007 AGXT2L1 -1.2 -1.3 -2.5 3.7 0.073 4q25
756556 SERPING1 1.3 1.2 1.4 3.6 0.048 11q12-q13.1
214162 MT1H 1.5 1.5 1.1 3.5 0.056 16q13
41447 AGTRL1 1.3 1.2 1.3 3.2 0.025 11q12
45544 TAGLN2 1.3 1.4 1.1 3.1 0.082 1q21-q25
44310 ELL -1.9 1.3 -3.1 2.9 0.153 19p13.1
487777 RB1 1.1 1.3 1.4 2.8 0.063 13q14.2
245774 C10orf10 1.4 -1.1 2.2 2.8 0.136 10q11.21
173145 CLIPR-59 -2.1 -1.1 -1.2 2.8 0.091 19q13.12
703479 HDHD1A 1.2 1.3 1.3 2.7 0.010 Xp22.32
244147 In multiple UG-clusters 1.3 2.2 1.2 2.7 0.095
839374 EXTL2 -1.6 -1.3 -1.1 2.7 0.032 1p21
1908973 CART 1.1 1.3 1.4 2.6 0.052 5q13.2
Schizophrenic patients were subdivided according to the antipsychotic medication received at death, and pooled brain samples were hybridized 
onto human cDNA microarrays. Twenty-three clones with large and consistent mRNA differences in all three sub-groups are listed together with 
their ranking statistic and parametric p-value. Four false positives are expected by chance in the list. Genes with a biological function involved in 
immune response (*, GO:0006955) were overrepresented in the list (p-value < 0.01). Listed P-values correspond to the parametric test of the 
average effect (across the subgroups) being different from the control (n = 3).BMC Psychiatry 2007, 7:46 http://www.biomedcentral.com/1471-244X/7/46
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accounting for infectious/non-infectious death cause, and
0.0006, 0.004, 0.003, 0.035 for the analysis excluding
subjects that died due to infectious causes.
A correlation analysis indicated that the four inflamma-
tion-related genes SERPINA3, IFITM2, IFITM3 and GBP1
were co-expressed in both schizophrenic subjects and
controls (Table 3). This correlation indicates that brain
samples with high mRNA levels of one gene also tended
to have high mRNA levels of the other three genes. This
implicates that the observed disturbance in schizophrenia
is indeed reflecting a coordinated transcriptional response
in several inflammation-related genes. Similarly, the
mRNA levels of the three OR genes (SCD, MAG and TF)
were also strongly co-expressed, which is in line with our
previous results on other OR genes [8]. We also note that
there is no strong correlation between inflammation-
related gene expression and expression of oligodendro-
cyte related genes, suggesting that the two sets of genes are
expressed relatively independent of each other in the
investigated samples.
Expression of immune-related genes in oligodendroglial 
and endothelial cell lines
As it has been suggested that schizophrenia may be the
consequence of a vascular-inflammation [14], we studied
the mRNA levels of SERPINA3, IFITM2, IFITM3, and
GBP1 in a human endothelial cell line (TIME), before and
after stimulation with TNF-α (Figure 2A). All four genes
were expressed and stimulated in the endothelial cell line.
The mRNA levels of SERPINA3 and GBP1 increased 80-
fold and 9.4-fold in response to TNF-α addition, and the
corresponding response of IFITM2 and IFITM3 was 3.8
and 3.4-fold respectively (p-values for the four genes were
0.0215, <0.0001, 0.0200 and 0.0118).
Since the expression of myelination genes is disturbed in
schizophrenia, we also decided to examine whether one
or more of the inflammation-related genes were expressed
in a human oligodendrocyte-cell line (HOG). Unexpect-
Table 2: Messenger RNA levels of immune response and oligodendrocyte related genes in frontal cortex of schizophrenic subjects as 
compared to control individuals, quantified by qPCR
Fold change F-ratio
Gene Schizo (n = 
55)
NTD (n = 11) Typical (n = 
7)
Atypical (n = 
7)
Schizo vs. Ctrl Subgroup
SERPINA3 3.6 4.4 2.2 7.6 20.7 *** 1.8
IFITM2 1.4 1.7 1.3 1.6 16.2 *** 1.8
IFITM3 1.4 1.7 1.2 1.5 16.3 *** 2.7
GBP1 1.5 1.6 1.6 2.0 6.9 ** 0.1
HLA-A 1.2 1.0 1.3 1.2 2.6 1.0
MAG -1.7 -1.8 -1.4 -3.5 9.5 ** 2.2
SCD -1.2 -1.5 1.1 -2.1 3.3 6.9 **
TF -1.4 -1.9 1.1 -3.2 5.1 * 7.9 ***
Schizophrenic patients have been subdivided according to the antipsychotic medication received at death. Mean levels across all schizophrenic 
subjects are compared to controls individuals (Schizo vs. Ctrl), and the heterogeneity between the three subgroups is tested (Subgroup). Asterisk 
(*) indicates statistically significant deviation from the null hypothesis (p-value <0.05, <0.01 and <0.001 for one, two and three asterisks, 
respectively).
Number of clones showing evidence of differential expres- sion in at least one subgroup of schizophrenic patients Figure 1
Number of clones showing evidence of differential 
expression in at least one subgroup of schizophrenic 
patients. Schizophrenic patients were subdivided according 
to the type of antipsychotic medication received at death, 
and pooled brain samples were hybridized onto 29.8 K 
cDNA microarrays. Bars represent the number of clones 
showing evidence of increased (white) or decreased (grey) 
mRNA levels in all (Schizo) or in at least in one of three 
schizophrenic subgroups (NTD, Typical, Atypical), as com-
pared to control individuals. Detailed lists of clones for each 
subgroup used to construct the figure are included as Supple-
mentary Tables 2, 3, and 4. The genes that were differentially 
expressed independently of received medication (Schizo) are 
listed in Table 1.BMC Psychiatry 2007, 7:46 http://www.biomedcentral.com/1471-244X/7/46
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edly, all four genes were expressed in HOG cells and their
expression was stimulated by inflammatory cytokines
(Figure 2B, C, D). In particular, the mRNA levels of GBP1
increased 24-fold (p < 0.001) with IFN-γ stimulation.
GBP1 expression was also stimulated by IFN-α and TNF-α
(p-values were, <0.0001, and 0.0022), but the response
was less pronounced in magnitude and time. IFITM2
expression was only induced by IFN-α (p = 0.0069) and
SERPINA3 was only significantly induced by TNF-α (p =
0.05).
Discussion
Immune-mediated inflammation is normally greatly
reduced in the brain, a phenomenon called immune priv-
ilege [23]. Immune mediated inflammation can have
severe consequences for the brain, which have limited
capacity for regeneration. We here show that four genes
involved in inflammatory response are up-regulated in
post-mortem frontal cortex samples from schizophrenic
subjects irrespective of neuroleptic treatment. That
inflammatory factors may be involved in the disease has
been scientifically discussed since the "epidemic" appear-
ance of psychotic disorders in 1845 [24]. For example,
signs of inflammation and microglia activation in post-
mortem brains, a dysfunctional blood brain barrier,
enhanced cytokine levels in the CSF preceding psychotic
episodes, and signs of T cell system activation, all point to
parallels between schizophrenia and autoimmune/infec-
tious disorders. Other indirect evidence to support that
early inflammation may contribute to the development of
schizophrenia include the facts that maternal infections
increase the risk of the disease [25], mice exposed to
cytokines in the uterus show behavioural alterations rele-
vant for schizophrenia [26-28], and an increased inci-
dence of the disease during the winter months [29].
Our results give additional support to the inflammatory
hypothesis for schizophrenia and provide four biological
markers for the disease likely to be directly involved in
inflammatory processes, namely GBP1, SERPINA3,
IFITM2, and IFITM3. GBP1, or Interferon-gamma-induci-
ble human guanylate binding protein 1, belongs to the
family of dynamin-related large GTP-binding proteins. It
is specifically induced by interferon gamma [30], and is a
marker for monitoring cytokine induced phenotype of
endothelial cells during inflammation [31]. SERPINA3 is
a member of the serine protease inhibitor superfamily. It
Cytokine stimulated gene expression in human cell lines Figure 2
Cytokine stimulated gene expression in human cell 
lines. A human endothelial cell line (TIME) was incubated 
with 10 ug TNF-α during 3, 8, 24 or 48 hours (A), while 
human oligodendroglial (HOG) cell cultures were incubated 
with either10 ng/ml IFN-γ (B), 10 ng/ml IFN-α (C) or 1 ng/ml 
TNF-α (D). Expression levels were quantified by qPCR and 
are shown relative to the expression levels in non-stimulated 
cells (defined as "zero") on a log2 scale. Mean and standard 
error of independent triplicate cell cultures are given.
Table 3: Correlation analysis of qPCR expression levels
Gene Name SERPINA3 IFITM2 IFITM3 GBP1 MAG SCD TF
SERPINA3 1.00 0.60 0.66 0.39 0.16 0.16 0.12
IFITM2 0.58 1.00 0.91 0.56 0.00 0.08 -0.04
IFITM3 0.60 0.90 1.00 0.60 0.11 0.16 0.02
GBP1 0.39 0.51 0.62 1.00 0.22 0.31 0.23
MAG -0.05 -0.16 -0.13 -0.14 1.00 0.88 0.93
SCD 0.14 -0.04 -0.04 -0.06 0.64 1.00 0.89
TF 0.14 0.01 -0.03 -0.09 0.76 0.81 1.00
The co-expression patterns of genes that were differentially expressed in schizophrenic subjects and/or varied between schizophrenic subgroups 
(IFITM2, IFITM3, SERPINA3, GBP1, SCD, MAG and TF) were explored for schizophrenic subjects and controls respectively. All pair-wise Pearson 
correlation coefficients were calculated on pPCR expression levels that remained after removing systematic variation that was due to factor such as 
diagnosis, schizophrenic subgroup, brain bank, age, post mortem time and reference gene expression (see details in Methods). Correlation of 
mRNA levels in the frontal cortex of schizophrenic subjects (below diagonal) and control individuals (above diagonal). Pearson correlation 
coefficients that were significant at the 0.01 levels have been outlined in bold.BMC Psychiatry 2007, 7:46 http://www.biomedcentral.com/1471-244X/7/46
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is required for the regulation of leukocyte proteases
released during an inflammatory response [32], and its
plasma levels increase more than four-fold in response to
inflammation [33]. IFITM2 and -3 are members of a fam-
ily of genes encoding interferon-induced transmembrane
proteins. Interestingly, mouse ifitm1 and -3, which are
expressed in primordial germ cells, also have important
and specific roles for cell development [34].
We observed coordinated increases in the expression lev-
els of these four genes in the brain of the schizophrenic
subjects. It is unlikely that our results are driven by spo-
radic infectious diseases late in life, as schizophrenic sub-
jects showed significantly elevated mRNA levels also
when the effect of infectious death cause was accounted
for in the analysis. Although alterations in these immune-
related transcripts are not sufficient evidence for inflam-
mation in schizophrenia, and these genes are not classic
indicators of chronic or acute inflammation, our results
indicate a significant alteration of inflammation-related
pathways. Thus, modifications in inflammatory-related
responses in the brain appear to be a common character-
istic for the progression of schizophrenia for a large group
of patients.
A recent theory postulates that schizophrenia may prima-
rily be a consequence of vascular inflammation in the
brain [14]. The theory proposes that abnormalities arise
because genetically modulated inflammatory reactions
damage the micro-vascular system in response to environ-
mental agents such as infections, hypoxia, and physical
trauma. To evaluate this hypothesis, we examined
whether inflammatory cytokines can induce the expres-
sion of the four genes in a human endothelial cell line.
Our  in-vitro  experiments demonstrated that GBP1,
SERPINA3, IFITM2, and IFITM3, could indeed be induced
by cytokine stimulation in endothelial cells. GBP1 is
known as a key mediator of the anti-proliferative effect of
inflammatory cytokines in endothelial cells [35]. The ele-
vated mRNA levels in schizophrenic subjects may thus
reflect changes in endothelial brain cells, with possible
long-term consequences for the micro-vascular system
during the progression of the disease.
Intriguingly, we also observed expression of inflamma-
tion related genes in oligodendroglial cells and induction
by cytokines in these cells. Our results indicate that oli-
godendroglial cells may indeed contain receptors for sev-
eral inflammatory cytokines and that the expression of
several inflammation-related genes can be induced by
these cytokines. It has recently been shown that inflam-
mation can modify myelination levels on transplanted
oligodendrocyte precursors [36]. Also, oligodendrocyte
precursor responses are dependent on the presence of
cytokines [37]. Thus, the observed increased expression of
GBP1, IFITM2, IFITM3 and SERPINA3 in schizophrenic
subjects may affect myelin producing cells, offering a pos-
sible link between the inflammatory and the myelin
hypothesis of the disease.
Pro-inflammatory agents appear to have little or no effect
on symptoms of schizophrenia [38,39]. On the other
hand, anti-inflammatory agents have been used for the
treatment of one patient, with improvement of negative
symptoms [40]. Our results may encourage future clinical
trials, aimed to determine whether anti-inflammatory
agents in combination with traditional neuroleptics can
be used as an effective treatment for positive and/or nega-
tive symptoms of schizophrenia.
Conclusion
Although the modified genes identified in this study are
not classical indicators of chronic or acute inflammation,
our results indicate that inflammation-related pathways
may be disturbed in the brain of schizophrenic subjects.
In addition, the observations in cell cultures suggest that
alterations in inflammatory-related genes may have con-
sequences for both vascular tissue and myelination.
Future research is needed to clarify whether cytokines
have indeed triggered the observed inflammation-related
response in the frontal cortex of schizophrenic subjects,
what specific cell types have been affected, and what the
consequences of these responses have for the develop-
ment of the disease. In parallel to such resaerch we hope
that our results may encourage future research exploring
whether anti-inflammatory agents can be used in combi-
nation with traditional antipsychotics for a more efficient
treatment of schizophrenia.
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